Novo Nordisk CEO Mike Doustdar is set to meet with investors and analysts today, facing intense scrutiny over the company’s corporate governance practices.
The meeting comes after the drugmaker’s decision to upgrade its 2026 financial outlook failed to stabilize share prices, signaling that market confidence remains fragile despite improved revenue expectations.
The disconnect between the positive corporate news and the market’s reaction highlights a deepening crisis of trust among Novo Nordisk’s investor base.
Shares fell sharply in early Monday trading in Copenhagen after a major shareholder publicly condemned the company’s oversight mechanisms, describing them as "extremely poor." This criticism has overshadowed the financial upgrades, suggesting that investors are prioritizing structural integrity over short-term earnings potential.
The sell-off extended to US markets, where Novo Nordisk’s American Depositary Receipts dropped significantly on Tuesday.
The persistent downward pressure indicates that the market is pricing in substantial risk related to the company’s internal management and board dynamics.